BioTryp Therapeutics has developed a class of small molecules that inhibit biofilm formation, a key defense mechanism used by bacteria to resist antibiotics. This technology targets biofilms in urinary tract infections, enhancing the effectiveness of existing antibiotic treatments and addressing the growing issue of antibiotic resistance.
Funding
$440K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Bacterial biofilms, present in a significant percentage of infections, act as a protective barrier against the immune system and antibiotics, leading to treatment failures and recurrent infections. Current antibiotic treatments often struggle to penetrate these biofilms, exacerbating the problem of antibiotic resistance.
Solution
BioTryp Therapeutics is developing small molecule antibiofilm agents that inhibit biofilm formation, addressing a key defense mechanism used by bacteria. These agents are designed to enhance the effectiveness of existing antibiotics by disrupting the biofilm's protective structure, allowing the antibiotics to more effectively target and eradicate the bacteria within. This approach offers a novel strategy to combat infections without directly contributing to antibiotic resistance, as the antibiofilm agents are not antibiotics themselves. BioTryp's technology is designed as an add-on therapy, working in conjunction with antibiotics to improve treatment outcomes.
Target Audience
The primary target audience includes patients suffering from bacterial infections, particularly UTIs, where biofilms contribute to treatment failure, as well as healthcare providers seeking more effective treatment options to combat antibiotic resistance.
Features
- Small molecule inhibitors of bacterial biofilm formation
- Designed to enhance the efficacy of existing antibiotic treatments
- Does not directly induce antibiotic resistance
- Applicable as an add-on therapy with a broad range of antibiotics
- Initial focus on Urinary Tract Infections (UTIs) due to the prevalence of biofilms in these infections
- Targets biofilms on the bladder wall and urinary catheters